Biotech Emmaus Holdings withdraws $29 million IPO

Comment

Shutterstock photo

Emmaus Holdings, or more commonly Emmaus Life Sciences, a biotech focused on the treatment of sickle cell disease and other rare diseases, withdrew its plans for an initial public offering on Friday. The company remains embroiled in a lawsuit with AFH Holdings since 2012, an advisory firm that was suppose to assist Emmaus in becoming a public company. The Torrance, CA-based company was founded in 2007 and last updated its filing in April 2012. Aegis Capital was set to be the sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines IPOs
Referenced Stocks: EMMA


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com